[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-376993-105":59,"doc-detail-376993-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","news-in-the-classification-of-who-2022-bladder-tumors-review","News in the classification of WHO 2022 bladder tumors - Review","","Review of the 2022 World Health Organization classification for tumors of the urinary system and male genital organs, focusing on bladder tumors and key updates since the 2016 fourth edition. Emphasizes morphology as the foundation of taxonomy while highlighting emerging molecular approaches for urothelial carcinoma classification and the growing role of immunotherapy. Details how grading is determined by architectural and cytological abnormalities and outlines clinical relevance of low-grade versus high-grade categories, including considerations for non-invasive lesions and invasive urothelial carcinoma grading.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/news-in-the-classification-of-who-2022-bladder-tumors-review/376993/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/news-in-the-classification-of-who-2022-bladder-tumors-review/376993.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the WHO 2022 classification update for bladder tumors?","Question",{"text":112,"@type":113},"It provides an update for classifying urinary tract tumors, including new insights into grading of heterogeneous non-invasive urothelial neoplasms, definitions of inverted neoplasms, and grading of invasive urothelial carcinomas.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is grading of urothelial neoplasms determined in the article?",{"text":117,"@type":113},"Grading is based on the degree of architectural and cytological disorders: low-grade shows mild nuclear atypia and preserved polarity, while high-grade shows marked architectural and cytologic abnormalities, loss of polarity, irregular pleomorphic nuclei, frequent mitoses, and anaplasia.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is distinguishing low-grade from high-grade important for patient management?",{"text":121,"@type":113},"The two-tier grading supports correlation with cytologic terminology (Paris System) and improves reproducibility while reducing interobserver variability, aligning with current patient management algorithms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},376993,1790636596,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PATHOLOGICA 2023;115:32-40; DOI: 10.32074/1591-951X-838  \nReceived: December 7, 2022  \nAccepted: December 12, 2022  \nCorrespondence  \nMaria Rosaria Raspollini  \nHistopathology and Molecular Diagnostics University Hospital Careggi, 50139 Florence, Italy  \nTel.: +39 055 794 9002  \n[E-mail: mariarosaria.raspollini@unifi.it](E-mail: mariarosaria.raspollini@unifi.it)  \nHow to cite this article: Raspollini MR, Comperat EM, Lopez-Beltran A, et al. News in the classification of WHO 2022 bladder tumors. Pathologica 2023;115:32-40 . [https://doi.org/10.32074/1591-951X-838](https://doi.org/10.32074/1591-951X-838)  \n© Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology  \n OPEN ACCESS  \nThis is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: [https://creativecommons](https://creativecommons). org/licenses/by-nc-nd/4.0/deed.en  \nReview  \nNews in the classification of WHO 2022 bladder tumors  \nMaria Rosaria Raspollini1 , Eva M. Comperat2 , Antonio Lopez-Beltran3 , Rodolfo Montironi4 , Alessia Cimadamore5 , Toyonori Tsuzuki6 , George J. Netto7  \n1 Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Florence, Italy;2 Department of Pathology, Medical University of Vienna, General Hospital of Vienna, Wien, AT, Austria; 3 University of Cordoba, Cordoba, Spain; 4 Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, Ancona, Italy; 5 Section of Pathological Anatomy, School of Medicine, University of Udine, Udine, Italy; 6 Department of Surgical Pathology, Aichi Medical University, Aichi, Japan; 7 Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA  \nSummary  \nThe fifth-edition of World Health Organization (WHO) Classification of Tumors series for urinary and male genital tract tumors has been published, six years later the fourth-edition. In these years, new treatment approaches have been implemented and new molecular data on urological cancers are known.  \nMorphology remains the groundwork for taxonomy of the urinary tract tumors. However, a molecular approach to classification of urothelial carcinomas and the management of selected neoplasms with new therapeutic modalities such as immunotherapy are emerging. More data are needed for the application of these advances in routine pathology practice and patient management.  \nThe 2022 World Health Organization (WHO) Classification of Tumors of the Urinary System and Male Genital Organs represents an update in classification on urinary tract tumors. It also offers new insights with regards to the grading of heterogeneous non-invasive urothelial neoplasms, the definition of inverted neoplasms, the grading of invasive urothelial carcinomas, the diversity of morphological appearance of urothelial carcinomas, the definition of precursor lesions and the lineage of differentiation of the tumors.  \nKey words: bladder, urothelial tumors, grading, molecular subgroups, WHO 2022  \nThe grading  \nThe grading of urotelial neoplasms is based on the level of architectural and cytological disorders. Low-grade carcinoma is characterized by lack of marked variation on nuclear size, mild loss of nuclear polarity and mild variation in nuclear size. High-grade carcinoma is characterized by marked architectural and cytologic disorders, loss of polarity, presence of irregular and pleomorphic nuclei, high number of mitoses and anaplasia.  \nThe two-tier distinction between low-grade and high-grade carcinomas was first proposed in the 1998 WHO/ISUP consensus 1 and this has been promulgated by WHO in the third 2 and the fourth 3 edition and maintained in the fifth 4.  \nLo","cbCaiaPQArkH1VKU","https://ap.wps.com/l/cbCaiaPQArkH1VKU","pdf",986527,"English","# Summary\n## The grading\n## Low-grade versus high-grade\n## Clinical implications for invasive and pT1 tumors","[{\"question\":\"What is the main purpose of the WHO 2022 classification update for bladder tumors?\",\"answer\":\"It provides an update for classifying urinary tract tumors, including new insights into grading of heterogeneous non-invasive urothelial neoplasms, definitions of inverted neoplasms, and grading of invasive urothelial carcinomas.\"},{\"question\":\"How is grading of urothelial neoplasms determined in the article?\",\"answer\":\"Grading is based on the degree of architectural and cytological disorders: low-grade shows mild nuclear atypia and preserved polarity, while high-grade shows marked architectural and cytologic abnormalities, loss of polarity, irregular pleomorphic nuclei, frequent mitoses, and anaplasia.\"},{\"question\":\"Why is distinguishing low-grade from high-grade important for patient management?\",\"answer\":\"The two-tier grading supports correlation with cytologic terminology (Paris System) and improves reproducibility while reducing interobserver variability, aligning with current patient management algorithms.\"}]","News in the classification of WHO 2022 bladder tumors - Review | PDF",1790222539,23]